Trial Outcomes & Findings for Radiofrequency of Breast Cancers in Non Surgical Patients (NCT NCT00210223)

Results Overview

The intervention was ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy. Recurrence was assessed based on follow-up with dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging).

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

21 participants

Primary outcome timeframe

one year

Results posted on

2025-10-01

Participant Flow

Participant milestones

Participant milestones
Measure	US-RF + Endocrine Therapy ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy: ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy
Overall Study STARTED	21
Overall Study COMPLETED	21
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	US-RF + Endocrine Therapy n=21 Participants ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy: ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy
Age, Continuous	79 years n=21 Participants
Sex: Female, Male Female	21 Participants n=21 Participants
Sex: Female, Male Male	0 Participants n=21 Participants
Region of Enrollment France	21 participants n=21 Participants

PRIMARY outcome

Timeframe: one year

The intervention was ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy. Recurrence was assessed based on follow-up with dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging).

Outcome measures

Outcome measures
Measure	US-RF + Endocrine Therapy n=21 Participants ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy: ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy
Number of Participants With Disease Recurrence One Year After the Intervention.	1 Participants

SECONDARY outcome

Timeframe: 5 years after the intervention

The intervention was ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy. Recurrence was assessed based on follow-up with dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging).

Outcome measures

Outcome measures
Measure	US-RF + Endocrine Therapy n=21 Participants ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy: ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy
Number of Participants With Disease Recurrence at 5 Years	4 Participants

Adverse Events

US-RF + Endocrine Therapy

Serious events: 0 serious events

Other events: 0 other events

Deaths: 4 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Simone Mathoulin-Pélissier

Institut Bergonié, Comprehensive Cancer Center, Bordeaux, FR

Phone: +33 5 56 33 33 33

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place